- Home
- GDTC vs MF Comparison
GDTC vs MF Comparison
Compare GDTC & MF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDTC | MF |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Singapore | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 9.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GDTC | MF |
|---|---|---|
| Price | $0.94 | $10.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.4K | ★ 70.7K |
| Earning Date | 04-24-2026 | 12-29-2022 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $5.07 |
| 52 Week High | $3.68 | $22.56 |
Technical Indicators
Market Signals| Indicator | GDTC | MF |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 45.77 |
| Support Level | $0.76 | $10.30 |
| Resistance Level | $1.07 | $18.97 |
| Average True Range (ATR) | 0.12 | 2.15 |
| MACD | -0.01 | -0.33 |
| Stochastic Oscillator | 41.71 | 29.12 |
Price Performance
Historical ComparisonAbout GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.